# COVID-19 Moderna mRNA1273 Vaccine

vaccine protocol for Persons Age 18 Years or Older

## Condition for protocol

To reduce incidence of morbidity and mortality of COVID-19 disease.

## Policy of protocol

The nurse will implement this protocol for COVID-19 vaccination using the Moderna mRNA1273 vaccine product.

## Condition-specific criteria and prescribed actions

[Instructions for persons adopting these protocols: The table below lists indication, contraindication, and precaution criteria and suggested prescribed actions that are necessary to implement the vaccine protocol. The prescribed actions include examples shown in brackets, but may not suit your institution’s clinical situation and may not include all possible actions. A licensed prescriber must review the criteria and actions and determine the appropriate prescribing action. **Delete this paragraph before signing protocol**.]

Indications

|  |  |
| --- | --- |
| **Criteria** | **Prescribed action** |
| Person is currently healthy and age 18 years or older | Proceed to vaccinate if meets remaining criteria. |
| Person is less than age 18 years. | Do not vaccinate. |
| Person is currently healthy but has a chronic medical condition. | Proceed to vaccinate. |
| Person is HIV positive, or immunocompromised, or is currently on immunosuppressive therapy. | Proceed to vaccinate. Counsel the individual about: 1) The unknown vaccine safety profile and effectiveness in immunocompromised populations. 2) The potential for reduced immune responses. 3) The need to continue to follow [current guidance](https://www.cdc.gov/coronavirus/2019-ncov/index.html) to protect themselves. |
| Person is pregnant. | Proceed to vaccinate if 1) the individual is part of a group considered at risk for exposure to SARS-CoV-2; AND 2) the individual has had an opportunity to discuss the risk and benefit of COVID-19 vaccination with their health care provider. |
| Person is lactating. | May vaccinate if the lactating person is part of a group recommended to receive a COVID-19 vaccine (e.g., healthcare personnel) and chooses to be vaccinated. |
| Person was given the first dose more than 28 days ago. | Proceed to administer the second dose if the product previously received was the Moderna mRNA1273 vaccine. |

Contraindications

|  |  |
| --- | --- |
| **Criteria** | **Prescribed action** |
| Person had a life-threatening allergic reaction (anaphylaxis) to a previous dose of Moderna mRNA1273 vaccine. | Do not vaccinate. |
| Person has had a life-threatening allergic reaction (anaphylaxis) to a component of the mRNA1273 vaccine.  *See listing below the prescription.* | Do not vaccinate. |

Precautions

|  |  |
| --- | --- |
| **Criteria** | **Prescribed action** |
| Person is currently ill due to COVID-19. | Defer vaccination. Instruct person to return when their infection is resolved and they have completed their isolation period. |
| Person was previously ill with COVID-19 and received monoclonal antibodies or convalescent plasma as part of COVID-19 treatment. | Defer vaccination until 90 days from date of last treatment. |
| History of severe allergic reaction (e.g., anaphylaxis) to any vaccine or injectable therapy (e.g., intramuscular, intravenous, or subcutaneous) | May be vaccinated, however they must be counseled on the unknown risks of developing a severe allergic reaction and balance these risks against the benefits of COVID-19 vaccination. Observe them for 30 minutes after vaccination.  Allergies not related to vaccines or injectable therapies (e.g., food, pet, environmental, or latex allergies; oral medications – including the oral equivalents of injectable medications) are not a contraindication or precaution to vaccination. |
| Person was exposed to another person with known COVID-19 disease. | Defer vaccination until the person’s quarantine period has ended.  If the person is a resident in a congregate setting, see [Interim Clinical Considerations for Use of mRNA COVID-19 Vaccines Currently Authorized in the United States (https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html)](https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html). |
| Person has received another non-COVID vaccine within the past 14 days. | Reschedule COVID-19 vaccine administration at least 14 days from the non-COVID vaccine date of administration. |

## Prescription

Give Moderna mRNA1273 vaccine; 100 micrograms, 0.5 mL, intramuscular (IM).   
Give the second dose 28 days following the first dose.

## Medical Emergency or Anaphylaxis

Follow pre-established agency protocol for anaphylaxis.

## Question or Concerns

In the event of questions or concerns, call \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_at (\_\_\_) \_\_\_\_-\_\_\_\_\_\_.   
*(Insert overseeing medical consultant’s information here.)*

This protocol shall remain in effect for all Minnesota residents until rescinded.

Name of prescriber: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Signature: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Date: \_\_\_\_\_\_\_\_\_\_\_\_\_\_

Document reviewed and updated: December 22, 2020

## Ingredient listing for Moderna mRNA1273 COVID-19 Vaccine

* 1.93 mg (SM-102, polyethylene glycol [PEG] 2000 dimyristoyl glycerol [DMG], cholesterol, and 1,2-distearoyl-sn-glycero-3-phosphocholine [DSPC])
* SM-102 (Proprietary to Moderna)
* 0.31 mg Tromethamine
* 1.18 mg Tromethamine hydrochloride
* 0.043 mg Acetic acid
* 0.12 mg Sodium acetate
* 43.5 mg Sucrose

Taken from the *FULL EMERGENCY USE AUTHORIZATION (EUA) PRESCRIBING INFORMATION MODERNA COVID-19 VACCINE*found in [Vaccination Provider Fact Sheet | EUA | Moderna COVID-19 Vaccine (www.modernatx.com/covid19vaccine-eua/eua-fact-sheet-providers.pdf)](http://www.modernatx.com/covid19vaccine-eua/eua-fact-sheet-providers.pdf).